InsidersTradesSigma
Follow the 昊帆生物 stock price and the full management transaction log of the company, a listed issuer based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 昊帆生物 has published 10 public disclosures. Market capitalisation: €6.1bn. The latest transaction was reported on 18 July 2024 (Purchase). Among the most active insiders: 徐杰. Every trade is free.
10
Insider Decl.
n/a
Thresholds
€1m
10 ops.
Buy Volume
n/a
n/a
Sell Volume
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,341 of 29,063 companies
46.2
score / 100
Value27
Quality65
FCF yld-2.2%
Earn yld1.9%
EV/EBITDA36.8x
ROE4.6%
Gross mgn35%
Net mgn19%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 July 2024
Declarations10 total
10 of 10 declarations
Acerca de 昊帆生物
昊帆生物 es una empresa enfocada en el sector de la salud y farmacéutico, especializada en el desarrollo de productos biofarmacéuticos. Cotiza en el mercado XSHE.